{rfName}
SO

Indexed in

License and use

Altmetrics

Analysis of institutional authors

Martin-Liberal, JAuthorHierro, CAuthorMesia, RicardAuthor

Share

Publications
>
Article

SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA

Publicated to:Future Oncology. 18 (34): 3791-3800 - 2022-11-01 18(34), DOI: 10.2217/fon-2022-0660

Authors: Prat, A; Paz-Ares, L; Juan, M; Felip, E; Garralda, E; González, B; Arance, A; Martín-Liberal, J; Gavilá, J; López-González, A; Cejalvo, JM; Izarzugaza, Y; Amillano, K; Corbacho, JG; Saura, C; Racca, F; Hierro, C; Sanfeliu, E; Gonzalez, X; Canes, J; Villacampa, G; Salvador, F; Pascual, T; Mesía, R; Cervantes, A; Tabernero, J

Affiliations

August Pi i Sunyer Biomed Res Inst IDIBAPS, Barcelona, Spain - Author
Catalan Inst Oncol ICO, Barcelona, Spain - Author
Complejo Asistencial Univ Leon, Leon, Spain - Author
Germans Trias I Pujol Res Inst IGTP, Catalan Inst Oncol ICO Badalona, Med Oncol Dept, Badalona Appl Res Grp Oncol B ARGO, Barcelona, Spain - Author
Hosp Clin Barcelona, Immunol Dept, Immunotherapy Platforms, Barcelona, Spain - Author
Hosp Clin Barcelona, Med Oncol Dept, Barcelona, Spain - Author
Hosp Clin Barcelona, Pathol Dept, Barcelona, Spain - Author
Hosp Univ 12 Octubre, Madrid, Spain - Author
Hosp Univ Fdn Jimenez Diaz, Madrid, Spain - Author
Hosp Univ Gen Catalunya, Inst Oncol Dr Rosell, Sant Cugat Del Valles, Spain - Author
Hosp Univ St Joan de Reus, Tarragona, Spain - Author
Inst Salud Carlos III, CIBERONC Ctr Invest Biomed Red Canc, Madrid, Spain - Author
Inst Valenciano Oncol IVO, Valencia, Spain - Author
IOB Hosp Quironsalud Barcelona, Barcelona, Spain - Author
SOLTI Canc Res Grp, Barcelona, Spain - Author
Univ Barcelona, Med Dept, Barcelona, Spain - Author
Univ Valencia, Hosp Clin Univ Valencia, INCLIVA Inst Invest Sanitaria, Valencia, Spain - Author
Vall dHebron Hosp Campus, Barcelona, Spain - Author
Vall dHebron Inst Oncol VHIO, Barcelona, Spain - Author
Vall dHebron Inst Oncol VHIO, Oncol Data Sci, Barcelona, Spain - Author
See more

Abstract

Keywords

AdultAdvanced melanomaBlockadeCancer immunotherapyClinical outcomeCohort analysisControlled studyDocetaxelDrug efficacyDrug responseDrug safetyDrug tolerabilityFemaleGene expressionHumanImmunotherapyLife expectancyMajor clinical studyMaleMalignant neoplasmMessenger rnaMetastasisMetastatic cancerMonotherapyMulticenter studyNivolumabOverall response rateOverall survivalPd-1PembrolizumabPhase 2 clinical trialPhase-2Programmed death 1 ligand 1Progression free survivalProtein expressionReviewSafetySingle-armSpartalizumabSquamous-cell carcinoma

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Future Oncology due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2022, it was in position , thus managing to position itself as a Q1 (Primer Cuartil), in the category Medicine (Miscellaneous).

From a relative perspective, and based on the normalized impact indicator calculated from the Field Citation Ratio (FCR) of the Dimensions source, it yields a value of: 2.18, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: Dimensions Jun 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-06-26, the following number of citations:

  • WoS: 3
  • Scopus: 5
  • OpenCitations: 4

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-06-26:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 5.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 5 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 4.6.
  • The number of mentions on the social network X (formerly Twitter): 9 (Altmetric).